Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Altimmune, Inc. (ALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Altimmune’s common stock, par value $0.0001 per share, is registered on The Nasdaq Global Market under the symbol ALT, and its Exchange Act and Securities Act filings offer detailed insight into its clinical, financial and corporate activities.
For a late clinical-stage company focused on peptide-based therapeutics for liver, metabolic and cardiometabolic diseases, periodic reports and current reports are particularly important. Forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) describe Altimmune’s business, risk factors, clinical programs and financial condition. Current reports on Form 8-K document material events, including clinical trial results for pemvidutide, Fast Track and Breakthrough Therapy designations, equity distribution agreements for at-the-market offerings, amendments to loan facilities, executive transitions and annual meeting outcomes.
Altimmune’s proxy materials, such as the definitive proxy statement on Form DEF 14A, outline governance matters, board composition, executive compensation and items submitted to stockholders at the annual meeting. These filings help investors understand how the company is overseen and how leadership is incentivized as it advances pemvidutide through Phase 2 and prepares for planned Phase 3 development in MASH.
On Stock Titan, Altimmune filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key terms in agreements such as loan amendments or equity distribution arrangements, and make it easier to locate information on topics like clinical milestones, financing capacity or voting results. Users can also review disclosures related to capital structure, including at-the-market programs and term loan facilities, to see how Altimmune funds its liver and cardiometabolic disease pipeline.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver completed an open-market purchase of 10,000 shares of common stock. The transaction, dated April 1, 2026, was executed at a weighted average price of $3.1499 per share and was made directly.
Following this purchase, Weaver directly owns 38,078 shares of Altimmune common stock. According to the footnote, the shares were bought in multiple trades, with prices ranging from $3.1450 to $3.1499 per share.
Altimmune, Inc. President and CEO Jerome Benedict Durso reported an open-market purchase of 15,000 shares of the company’s common stock at $3.14 per share.
Following this transaction, his directly held Altimmune common stock position increased to 47,500 shares.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting its position in Altimmune Inc. The filing states 0 shares beneficially owned and 0% of the class. The amendment explains an internal realignment and separate reporting by Vanguard subsidiaries in accordance with SEC Release No. 34-39538.
Altimmune, Inc. has released its 2026 proxy for a virtual annual meeting on April 16, 2026. Shareholders of record as of March 13, 2026, when 130,105,177 common shares were entitled to vote, are asked to elect nine directors and ratify Ernst & Young LLP as auditor.
Investors will also cast an advisory vote on executive pay, consider doubling authorized common stock from 200,000,000 to 400,000,000 shares, and vote on expanding the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares. A proposal to allow adjournment to solicit more proxies is also included.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver bought 5,000 shares of the company’s common stock in an open-market purchase at a price of $3.54 per share. After this transaction, he directly owns 28,078 common shares of Altimmune.
Altimmune, Inc. director, President and CEO Jerome Benedict Durso reported an open-market purchase of 20,000 shares of common stock. The shares were bought at a weighted average price of $3.5395 per share in multiple trades between $3.53 and $3.55.
Following this transaction, Durso now directly owns 32,500 shares of Altimmune common stock. The purchase reflects an increase in his direct equity stake through open-market buying.
Altimmune, Inc. will hold its 2026 virtual Annual Meeting on April 16, 2026 (8:30 a.m. ET); the record date was March 13, 2026. Stockholders will vote on six proposals: election of nine directors; ratification of Ernst & Young LLP as auditor; an advisory "say-on-pay" vote; an amendment to increase authorized common stock from 200,000,000 to 400,000,000; an amendment to the 2019 Employee Stock Purchase Plan to increase the reserve to 1,108,827 shares; and authorization to adjourn.
The proxy materials state there were 130,069,983 shares issued and outstanding as of March 1, 2026, 17,226,344 shares issuable under an at-the-market offering and 18,720,227 shares issuable or available under incentive plans; if issued, those would total 166,016,554 shares outstanding, leaving 33,983,446 authorized but unissued under the current charter. The Board recommends voting FOR all proposals.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on serious liver diseases, led by its dual glucagon/GLP‑1 agonist pemvidutide for MASH, alcohol use disorder and alcohol‑associated liver disease. More than 700 patients have received pemvidutide across 8 completed and 2 ongoing studies.
In the IMPACT Phase 2b MASH trial, 24‑week data showed MASH resolution without worsening fibrosis in 58.2% and 52.1% of patients on pemvidutide 1.2 mg and 1.8 mg, versus 19.9% on placebo, and significant improvements in non‑invasive fibrosis markers. Pemvidutide has Breakthrough Therapy and Fast Track designations for MASH.
For 2025, Altimmune reported a net loss of $88.1 million, improving from a $95.1 million loss in 2024, as research and development expenses fell 19% to $66.4 million while general and administrative costs rose 34% to $28.1 million. Cash, cash equivalents, restricted cash and short‑term investments were $273.5 million as of December 31, 2025, and management believes this will fund operations for at least twelve months from the financial statement issuance date.
Altimmune, Inc. reported 2025 results showing it remains a late-stage clinical biopharma focused on pemvidutide for serious liver diseases. For 2025, the company recorded a net loss of $88.1 million, improving from $95.1 million in 2024, as research and development spending fell to $66.4 million from $82.2 million. General and administrative expenses rose to $28.1 million from $21.0 million. Net loss per share narrowed to $1.00 from $1.34, on higher weighted-average shares.
Altimmune ended 2025 with $274.0 million in cash, cash equivalents and short-term investments and subsequently strengthened its balance sheet with a $75 million registered direct offering in January 2026 and a noncurrent term loan of $34.3 million. The lead asset pemvidutide received FDA Breakthrough Therapy Designation for MASH and Fast Track designations for MASH and AUD. The company plans to initiate a Phase 3 MASH trial in 2026 and expects topline data from its Phase 2 pemvidutide trial in alcohol use disorder in the third quarter of 2026, while a Phase 2 trial in AUD and the RESTORE trial in alcohol-associated liver disease continue.